Additionally, the highly selective Bcl-2 inhibitor, Venetoclax (VIII), is now approved for treatment of chronic lymphocytic leukemia (CLL) patients with a 17p chromosomal deletion who have received at least one prior therapy (Figure 2) [42,43]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.